Cargando…
FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
BACKGROUND: FGFR1 amplification, but not overexpression, has been related to adverse prognosis in hormone-positive breast cancer (HRPBC). Whether FGFR1 overexpression and amplification are correlated, what is their distribution among luminal A or B HRPBC, and if there is a potential different progno...
Autores principales: | Mouron, Silvana, Manso, Luis, Caleiras, Eduardo, Rodriguez-Peralto, Jose L., Rueda, Oscar M., Caldas, Carlos, Colomer, Ramon, Quintela-Fandino, Miguel, Bueno, Maria J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881584/ https://www.ncbi.nlm.nih.gov/pubmed/33579347 http://dx.doi.org/10.1186/s13058-021-01398-8 |
Ejemplares similares
-
Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition
por: Quintela-Fandino, Miguel, et al.
Publicado: (2019) -
FGFR1 is an adverse outcome indicator for luminal A breast cancers
por: Shi, Yu-Jie, et al.
Publicado: (2015) -
Personalising and targeting antiangiogenic resistance: a complex and multifactorial approach
por: Bueno, Maria J, et al.
Publicado: (2017) -
FGFR2 amplification in colorectal adenocarcinoma
por: Carter, Jamal H., et al.
Publicado: (2017) -
FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes
por: Furugaki, Koh, et al.
Publicado: (2023)